Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MINT-2: De-escalated Adjuvant Therapy for HPV-Related Oropharynx Cancer
NCT06702033Phase 2Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2025
- Primary completion
- Apr 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Cisplatin micelle injection (HA132) in oropharyngeal squamous cell carcinoma (OPSCC), sponsored by Washington University School of Medicine. Started Apr 2025; status: recruiting.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT06702033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06702033.